Table 2.
Base-case analysis results for caspofungin- versus fluconazole-initiated treatment strategies for hospitalized Ethiopian patients with IC/C
| Treatment Strategies | Incremental | ||||||
|---|---|---|---|---|---|---|---|
|
CASPO
->
L-AmB
[1] |
FLU
->
CASPO
->
L-AmB
[2] |
FLU
->
L-AmB
[3] |
[1] vs. [2] | [2] vs. [3] | [1] vs. [3] | ||
| Discounted at 3% | |||||||
| Life years | 13.81 | 13.21 | 11.73 | 0.60 | 1.48 | 2.08 | |
| QALY | 12.86 | 12.30 | 10.92 | 0.56 | 1.38 | 1.94 | |
| Cost (US$ 2021) | 7714 | 3217 | 2781 | 4497 | 436 | 4933 | |
| ICUR (US$/QALY) | - | - | - | 8030 | 316 | 2543 | |
| Undiscounted (0%) | |||||||
| Life years | 20.69 | 19.67 | 17.18 | 1.02 | 2.49 | 3.51 | |
| QALY | 19.25 | 18.31 | 15.99 | 0.94 | 2.33 | 3.26 | |
| Cost (US$ 2021) | 10,748 | 3329 | 2875 | 7,419 | 454 | 7873 | |
| ICUR (US$/QALY) | - | - | - | 7893 | 196 | 2415 | |
CASPO: Caspofungin; FLU: Fluconazole; L-AmB: Liposomal amphotericin B